Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on
HeartBeam, Inc. (NASDAQ: BEAT) announced an expansion of its clinical validation study to include a broader patient population for its emergency department software technology. The decision follows the recent AHA guidelines and aims to include unstable angina patients, which may enhance heart attack detection. HeartBeam plans to file a 510K submission by August 15, 2022, which remains unaffected by the Telehealth product's timeline, scheduled for Q4 2022. This expanded scope aligns with their goal of improving cardiovascular diagnosis.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare innovator, will present at the LD Micro Invitational XII Conference from June 7-9, 2022, in Westlake Village, CA. CFO Rick Brounstein and CBO Jon Hunt, PhD, will host 25-minute meetings and deliver a presentation on June 7 at 4:00 pm ET. HeartBeam specializes in proprietary ECG telemedicine technology aimed at improving heart attack detection outside medical institutions. This significant advancement addresses the high-risk cardiovascular patient population's needs. For more details, visit ir.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) will participate virtually in the H.C. Wainwright Global Investment Conference from
The company's CEO, Branislav Vajdic, CFO Rick Brounstein, and CBO Jon Hunt will conduct one-on-one meetings during the event. Jon Hunt will also deliver a virtual presentation available on-demand starting
This innovative digital healthcare company focuses on ECG telemedicine technology for heart attack detection, providing significant advancements in diagnosing cardiovascular diseases outside medical institutions.
HeartBeam, a digital healthcare company (NASDAQ: BEAT), reported its Q1 2022 results, highlighting a net loss of $2.1 million, up from $210,000 in Q1 2021. R&D expenses increased significantly to $734,000, compared to $29,000 in the prior year. The company remains on track for an FDA submission for its Emergency Department Myocardial Infarction software in Q2 2022 and a Telehealth solution in Q4 2022. With cash reserves of $11.2 million, HeartBeam anticipates a full commercial rollout of its ED Software Tool in Q1 2023.
The acquisition of RedCrow by Alira Health aims to enhance access to alternative investments in healthcare startups. Founded in 2016, RedCrow has raised $250 million through over 250 fundraises. This strategic move allows Alira to extend its patient engagement mission by involving them in the financing of new healthcare solutions. The financial terms of the acquisition remain undisclosed, but the collaboration is expected to democratize healthcare investing, promoting innovation in early-stage pharma and MedTech.
HeartBeam, Inc. (NASDAQ: BEAT) announces a conference call on May 12, 2022 at 4:30 p.m. Eastern time, to discuss its first-quarter results for the period ending March 31, 2022. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. Participants can join via telephone or webcast. A replay will be available until July 12, 2022. HeartBeam specializes in digital healthcare technology for heart attack detection using an innovative ECG device. For further details, visit www.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.
HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
